IRIDEX Corporation
IRIDEX Corp is an ophthalmic medical technology company that develops and commercializes laser-based systems and related therapies for sight-threatening eye diseases. Its core focus is on glaucoma and retinal disorders, using proprietary MicroPulse and Endpoint Management technologies to deliver tissue-sparing treatment modes in select laser consoles.
Tilikausi 2026 · muutos edellisvuodesta
Kehitys 2019–2026
Liiketoiminta
Osuus liikevaihdostaLaser-based products and treatment modes used to manage glaucoma, including Cyclo G6.
Products and procedures used to treat retinal diseases and related eye conditions.
Additional ophthalmic devices, accessories, and related product sales outside the core glaucoma and retina groups.
Service revenue and support activities tied to installed systems and customer use.
Tuotteet
Raportoitu · osuus liikevaihdosta- Retina57,5 %
- Cyclo G Six26,3 %
- Other16,2 %
Lähde: 10-K FY2026, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
IRIDEX sells primarily to eye-care providers that need capital equipment and treatment solutions for glaucoma and retinal disease. Its customers include hospitals, surgical centers, physician offices, and international distributors that resell or place the company’s systems in local markets. Demand depends on clinical adoption, purchasing budgets, and the timing of capital equipment decisions.
Buy ophthalmic laser systems for glaucoma and retina procedures, often as capital equipment tied to procedure volume.
Purchase systems for in-office treatment of sight-threatening eye conditions and to expand procedure offerings.
Buy or place products for resale outside the U.S., extending market reach and local service coverage.
Adopt proprietary treatment modes because they can deliver low-energy, tissue-sparing therapy.
Strategia
IRIDEX is focused on commercializing its proprietary laser therapy technologies and expanding adoption in glaucoma and retina care. Near term, management is balancing product development, sales and marketing investment, and manufacturing efficiency while preserving liquidity and supporting new product introductions.
MicroPulse and Endpoint Management differentiate the company’s systems and support clinical adoption.
Revenue growth depends on converting clinical demand into capital equipment purchases and procedure use.
The company expects current cash to cover 12 months, but future growth may require additional capital.
Gross margin is sensitive to manufacturing costs, product mix, and international mix.
Maantiede
IRIDEX is headquartered in the United States, but it also sells internationally through distributors and direct end users. The company noted that direct end-user sales through its German office are denominated in euros, while distributor sales are generally denominated in U.S. dollars. International mix matters because it affects pricing, foreign exchange exposure, and gross margin.
Riskit
IRIDEX is exposed to cyclical capital equipment demand, since hospitals and physician offices can delay purchases when macroeconomic conditions weaken. The business also faces foreign exchange, tariff, and trade-war related pressure, while its small scale and ongoing investment needs create financing and execution risk.
- Tariffs and trade-war related cost inflationVaikutus: KorkeaTodennäköisyys: Korkea
Imported components and cross-border sales can be affected by tariff changes and retaliatory actions.
Kohdistuu: Manufacturing costs and international demand
- Delayed capital equipment purchasing by customersVaikutus: KorkeaTodennäköisyys: Kohtalainen
Hospitals, surgical centers, and physician offices may defer buying laser systems during recessionary or uncertain periods.
Kohdistuu: Revenue timing and order conversion
- Margin compression from product and geographic mixVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Capital system sales and international mix can lower gross margin when manufacturing costs rise.
Kohdistuu: Gross profit and operating leverage
- Financing and dilution riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
The company may need additional capital for R&D, sales expansion, or manufacturing investment.
Kohdistuu: Liquidity and shareholder dilution
- Foreign exchange pressure on international salesVaikutus: Keskitaso
A stronger U.S. dollar can make products more expensive abroad and reduce demand or profitability in local markets.
Kohdistuu: International distributor and euro-denominated direct sales
Kirjanpito
Harkinnanvaraiset erätEquipment, services, and distributor sales may be recognized differently depending on delivery and contract terms.
Vaikutus: Affects quarterly revenue timing and comparability
Cost of revenues includes components, labor, overhead, warranty, and third-party manufacturing costs.
Vaikutus: Directly affects gross margin
German office sales are denominated in euros and distributor sales are in U.S. dollars.
Vaikutus: Can change reported revenue and profitability
Recent financing can create dilution and require careful classification and measurement.
Vaikutus: Affects capital structure and per-share results
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
GLAUKOS Corp
GKOS · Surgical & Medical Instruments & Apparatus
Glaukos Corp develops and commercializes ophthalmic therapies and devices focused on glaucoma, corneal disorders, and emerging anterior/posterior segment treatments.
iRadimed Corporation
IRMD · Surgical & Medical Instruments & Apparatus
IRADIMED Corp designs and sells MRI-compatible medical devices used inside scanner rooms, centered on infusion pumps, patient vital signs monitoring systems, and related disposables and service.
RetinalGenix Technologies Inc.
RTGN · Surgical & Medical Instruments & Apparatus
IR-Med, Inc.
Electromedical & Electrotherapeutic Apparatus
Ocular Therapeutix, Inc
OCUL · Pharmaceutical Preparations
Streamex Corp.
STEX · Security & Commodity Brokers, Dealers, Exchanges & Services
Päivitetty: 24.9.2026